The goal of this project is to achieve a molecular understanding of the oncogenicity of phosphatidylinositol 3-kinase (PI3K). The proposed work will use two basic approaches: (1) a genetic analysis of the oncogenic functions of p1101, the catalytic subunit of PI3K, and (2) genome-wide interrogations for novel regulators and targets of PI3K. The genetic analysis will concentrate on the interactions between p1101 and Ras as well as p1101 and p85. These interactions are critical to the oncogenicity of p1101;they are fundamentally changed in the cancer-specific gain-of-function mutants of p1101. The p1101 protein carrying cancer-specific mutations in the helical domain (E542K, E545K) has requirements for p85- and Ras-binding that are opposite to those of the kinase domain mutant (H1047R). The helical domain mutants depend on Ras-binding but are largely independent of p85-binding. The kinase domain mutant does not require Ras but needs p85 to be active. We plan to analyze mutants of p85 and of Ras in which specific functions are disabled for their ability to activate wild-type and mutant p1101. This genetic analysis will advance our understanding of the molecular mechanisms by which cancer-specific mutations in p1101 induce a gain-of-function and make the protein oncogenic. The genome-wide interrogations for regulators and targets will take advantage of two new technologies. (1) A screen of expression libraries in the yeast Saccharomyces cerevisiae. This is a lethality screen based on the fact that expression of PI3K is toxic to Saccharomyces cerevisiae. The observed growth defect can be rescued by the expression of negative regulators of PI3K. Using this screen, we have identified several novel suppressors of PI3K. We will characterize these regulators and define the signaling chains that connect them to PI3K. (2) The second technology is a kinome screen that uses the two universally conserved lysines in ATP pockets of kinases to tag ATP-binding proteins by covalent linkage to biotin. We have used this method to reveal PI3K-induced changes in the kinome and, during initial studies, have identified three growth-regulatory kinases that are differentially expressed in PI3K- transformed cells. The roles of these and additional PI3K targets identified by the kinome screen will be analyzed and determined.

Public Health Relevance

Project Narrative - Relevance The cancer-specific gain-of-function mutants of p1101, the catalytic subunit of PI3K, constitute the most promising therapeutic targets currently available. A complete understanding of these mutant proteins, their wild-type counterparts and their oncogenic actions is necessary to take advantage of this unique opportunity for developing novel, targeted cancer therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA078230-13
Application #
7991365
Study Section
Cancer Genetics Study Section (CG)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
1998-09-10
Project End
2013-11-30
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
13
Fiscal Year
2011
Total Cost
$421,871
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
781613492
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Athuluri-Divakar, Sai Krishna; Vasquez-Del Carpio, Rodrigo; Dutta, Kaushik et al. (2016) A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell 165:643-55
Hart, Jonathan R; Zhang, Yaoyang; Liao, Lujian et al. (2015) The butterfly effect in cancer: a single base mutation can remodel the cell. Proc Natl Acad Sci U S A 112:1131-6
Hart, Jonathan R; Garner, Amanda L; Yu, Jing et al. (2014) Inhibitor of MYC identified in a Kröhnke pyridine library. Proc Natl Acad Sci U S A 111:12556-61
Ito, Yoshihiro; Hart, Jonathan R; Ueno, Lynn et al. (2014) Oncogenic activity of the regulatory subunit p85β of phosphatidylinositol 3-kinase (PI3K). Proc Natl Acad Sci U S A 111:16826-9
Raffeiner, Philipp; Röck, Ruth; Schraffl, Andrea et al. (2014) In vivo quantification and perturbation of Myc-Max interactions and the impact on oncogenic potential. Oncotarget 5:8869-78
Valeri, Nicola; Braconi, Chiara; Gasparini, Pierluigi et al. (2014) MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 25:469-83
Grabinski, Nicole; Ewald, Florian (2014) Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs 32:1096-104
Hart, Jonathan R; Roberts, Thomas C; Weinberg, Marc S et al. (2014) MYC regulates the non-coding transcriptome. Oncotarget 5:12543-54
Vogt, Peter K (2012) Retroviral oncogenes: a historical primer. Nat Rev Cancer 12:639-48
Kolesnichenko, Marina; Hong, Lixin; Liao, Rong et al. (2012) Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence. Cell Cycle 11:2391-401

Showing the most recent 10 out of 54 publications